JG
KDNY

Jefferies Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Jefferies Group’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,839
Closed -$15K – 3133
2019
Q3 		$15K Sell
2,839
-1,827
-39% -$12.1K ﹤0.01% 2638
2019
Q2 		$36K Sell
4,666
-5,161
-53% -$78.6K ﹤0.01% 2396
2019
Q1 		$196K Sell
9,827
-14,056
-59% -$245K ﹤0.01% 1953
2018
Q4 		$315K Buy
23,883
+14,577
+157% +$291K ﹤0.01% 1637
2018
Q3 		$342K Buy
9,306
+6,746
+264% +$217K ﹤0.01% 1813
2018
Q2 		$90K Buy
+2,560
New +$98.2K ﹤0.01% 2156
2016
Q3 		– Sell
-4,134
Closed -$234K – 2520
2016
Q2 		$234K Buy
4,134
+1,514
+58% +$92K ﹤0.01% 1753
2016
Q1 		$168K Buy
2,620
+1,400
+115% +$113K ﹤0.01% 1879
2015
Q4 		$172K Buy
+1,220
New +$166K ﹤0.01% 1973

Other funds holding KDNY

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's KDNY Position: Q4 2019 in Review

Jefferies Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2019, closing a stake of 2,839 shares — an estimated $15K sold.

Jefferies Group first reported a position in KDNY in Q4 2015 and held it in 9 quarters. The position peaked at $342K in Q3 2018. 84 funds tracked by Wall St. Rank hold KDNY as of Q4 2019.

  • Jefferies Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Jefferies Group sold 2,839 Chinook Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $15K.
  • Jefferies Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 9 quarters.
  • Jefferies Group's Chinook Therapeutics, Inc. Common Stock position peaked at $342K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.